Loading company…
Relief Therapeutics Holding AG is a Geneva-based biopharmaceutical company developing therapies for specialty, rare and ultra-rare diseases.
Relief Therapeutics develops and commercializes patent-protected therapies for patients with specialty, rare and ultra-rare diseases, distributed through partnerships in Europe and North America. Founded in 2013 and headquartered in Geneva, Switzerland, the company is led by CEO Michelle Lock. Its most recent round was a PIPE in July 2021 raising CHF 15.000 mn, and it reported revenue of CHF 6,373,873.4 and EBITDA of CHF -50,500,447.1 for fiscal 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in